Vivos Therapeutics
VVOS
20 hedge funds and large institutions have $802K invested in Vivos Therapeutics in 2025 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 1 reducing their positions, and 4 closing their positions.
700% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 1
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
0% more funds holding
Funds holding: 20 → 20 (0)
4.86% less ownership
Funds ownership: 9.65% → 4.78% (-4.9%)
60% less capital invested
Capital invested by funds: $2M → $802K (-$1.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Envestnet Asset Management
Chicago,
Illinois
|
+$153K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$126K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$70.7K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$49.2K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$49.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$1.04M |
| 2 |
SWIG
Strategic Wealth Investment Group
Louisville,
Kentucky
|
-$429K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$1.54K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$691 |
| 5 |
TWC
TD Waterhouse Canada
Toronto,
Ontario, Canada
|
-$51 |
VVOS Hedge Fund Activity: Q1 2025 in Review
20 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Vivos Therapeutics (VVOS) for Q1 2025, worth a combined $802K — down 60% from $2M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new VVOS positions and 4 closed out — a net gain of 1 holder — while 8 added to existing stakes and 1 trimmed.
The largest buyer was Envestnet Asset Management, opening a new position worth an estimated $153K. The largest seller was Anson Funds Management, exiting entirely with an estimated $1.04M sold.
- 20 institutional investors held Vivos Therapeutics (VVOS) as of Q1 2025, unchanged from Q4 2024.
- Funds reported $802K of Vivos Therapeutics stock for Q1 2025, down 60% quarter-over-quarter.
- 5 funds opened new Vivos Therapeutics positions in Q1 2025 and 4 closed out, a net change of +1 holder.
- The largest Vivos Therapeutics buyer in Q1 2025 was Envestnet Asset Management, an estimated $153K added.
- The largest Vivos Therapeutics seller in Q1 2025 was Anson Funds Management, an estimated $1.04M sold.
Based on aggregated 13F filings for Q1 2025.